First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
First-line MET TKI improved outcomes in PD-L1 <50% and brain/bone metastases, whereas ICI ± chemotherapy prolonged PFS only in PD-L1 ≥80%, emphasizing the need for personalized treatment selection.
Authors
- Julia Rotow (ORCID: https://orcid.org/0000-0003-4547-2960)
- Xinan Wang (ORCID: https://orcid.org/0000-0001-5236-1105)
- Jia Wu (ORCID: https://orcid.org/0000-0001-8392-8338)
- Xiuning Le (ORCID: https://orcid.org/0000-0002-8554-1185)
- Federica Pecci (ORCID: https://orcid.org/0009-0000-9289-2007)
- Edoardo Garbo (ORCID: https://orcid.org/0000-0003-2394-9895)
- Don L. Gibbons (ORCID: https://orcid.org/0000-0003-2362-3094)
- Francesco Gelsomino (ORCID: https://orcid.org/0000-0002-9204-1728)
- Marcelo Vailati Negrao (ORCID: https://orcid.org/0000-0001-8938-6699)
- Lingzhi Hong (ORCID: https://orcid.org/0000-0001-6553-3279)
- Biagio Ricciuti (ORCID: https://orcid.org/0000-0002-0651-2678)
- Andrea Ardizzoni (ORCID: https://orcid.org/0000-0003-2678-0714)
- Giulio Metro (ORCID: https://orcid.org/0000-0002-4978-9212)
- Valentina Santo (ORCID: https://orcid.org/0009-0006-7587-9445)
- John Victor Heymach (ORCID: https://orcid.org/0000-0001-9068-8942)
- Pasi Antero Janne (ORCID: https://orcid.org/0000-0002-7821-4928)
- Francesco Mantuano (ORCID: https://orcid.org/0009-0005-3111-5067)
- Hai T. Tran (ORCID: https://orcid.org/0000-0003-4065-9355)
- Mihaela Aldea (ORCID: https://orcid.org/0000-0001-7685-051X)
- Alfredo Addeo (ORCID: https://orcid.org/0000-0003-0988-0828)
- Alessandro Di Federico (ORCID: https://orcid.org/0000-0001-8877-4315)
- Marcello Tiseo (ORCID: https://orcid.org/0000-0002-9553-8465)
- Andrea De Giglio (ORCID: https://orcid.org/0000-0002-0731-5721)
- Mark M. Awad (ORCID: https://orcid.org/0000-0003-0928-5244)
- Francesco Paoloni (ORCID: https://orcid.org/0000-0002-8992-3578)
- Eleonora Gariazzo (ORCID: https://orcid.org/0009-0002-1665-3367)
- Jianjun Zhang (ORCID: https://orcid.org/0000-0001-7872-3477)
- J. Jack Lee (ORCID: https://orcid.org/0000-0001-5469-9214)
- Hong Chen (ORCID: https://orcid.org/0000-0001-8054-7417)
- Hui Li (ORCID: https://orcid.org/0000-0001-8161-0238)
- Guilherme Rossato de Almeida (ORCID: https://orcid.org/0009-0000-6073-6130)
Institutions
- University of Parma (IT)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- University of Perugia (IT)
- Harvard University Press (US)
- Cancer Research And Biostatistics (US)
- University Hospital of Geneva (CH)
- Dana-Farber Cancer Institute (US)
- Azienda USL di Bologna (IT)
- University of Bologna (IT)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1735
- Citations
- 4
- Primary Topic
- Metastasis and carcinoma case studies
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Eli Lilly and Company
- Spectrum Pharmaceuticals
- Regeneron Pharmaceuticals
- European School of Oncology
- National Institutes of Health
- EMD Serono
- National Cancer Institute